Supplementary Figures S1-S11 from Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab
Ayano Oashi(Keio University), Kenzo Soejima(Keio University), Keigo Kobayashi(Keio University), Keita Masuzawa(Kitasato Institute Hospital), Shinnosuke Ikemura(Keio University), Hideki Terai(Kitasato Institute Hospital), Junko Hamamoto(Keio University), Hiroyuki Yasuda, Ichiro Kawada(Keio University), Tadashi Manabe(Keio University), Katsuhiko Naoki(Broad Institute), Tetsuo Tani(Keio University)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101